MSD

Zilovertamab Vedotin (MK2140)

Biodrugs/ Drugs
Cancer
A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
2Phase II in Spain, 1Phase I